China Merchants Bank, a Chinese bank, and Mirae, a financial services group, led a $120m Series C funding round in EpimAb, a start-up biotech company. The round was joined by Hony Capital, Cormorant Asset Management, Yanchuang Capital, Octagon Capital, Adrian Cheng, ShangBay Capital, Decheng Capital, SDIC Fund, Sherpa Healthcare Partners and Hidragon Capital. “The completion of our Series C financing will enable us to accelerate the development of our three clinical assets EMB-01, EMB-02 and EMB-06, and to advance our rich pipeline of preclinical programs into the clinic as we continue to build on our portfolio of novel bispecific antibodies generated based on our proprietary FIT-Ig technology. We greatly appreciate the support from our new and current investors as we move into this next phase of our company’s development and remain committed to bringing innovative bispecific antibody therapeutics to patients worldwide,” Chengbin Wu, EpimAb Biotherapeutics Founder and CEO.